An unfavorable course of COVID-19 under ocrelizumab: a case report

Authors
Category Primary study
JournalTijdschr. Geneeskd. Gezondheidszorg
Year 2026
This article has no abstract
Epistemonikos ID: fb16f271ee4368af0606a316397d29ef52e7f778
First added on: Apr 28, 2026